{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:42:13Z","timestamp":1790214133619,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-025-01542-9","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T11:07:39Z","timestamp":1738408059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The effects of ursodeoxycholic acid on Parkinson\u2019s disease, a mechanistic review of the recent evidence"],"prefix":"10.1007","volume":"40","author":[{"given":"Seyed Mehrad","family":"Razavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niusha","family":"Esmaealzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Ataei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Afshari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moloud","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Hasrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Ghazizadeh Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolghasem","family":"Mortazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Mohaghegh Shalmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Abdolghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"issue":"2","key":"1542_CR1","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s12035-014-9043-8","volume":"53","author":"NF Abdelkader","year":"2016","unstructured":"Abdelkader NF, Safar MM, Salem HA (2016) Ursodeoxycholic acid ameliorates apoptotic Cascade in the Rotenone Model of Parkinson\u2019s Disease. Modulation Mitochondrial Perturbations Mol Neurobiol 53(2):810\u2013817","journal-title":"Modulation Mitochondrial Perturbations Mol Neurobiol"},{"key":"1542_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3389\/fnagi.2016.00263","volume":"8","author":"HD Ackerman","year":"2016","unstructured":"Ackerman HD, Gerhard GS (2016) Bile acids in neurodegenerative disorders. Front Aging Neurosci 8:263","journal-title":"Front Aging Neurosci"},{"key":"1542_CR3","doi-asserted-by":"publisher","first-page":"101840","DOI":"10.1016\/j.arr.2022.101840","volume":"85","author":"MH Ahmad","year":"2023","unstructured":"Ahmad MH, Rizvi MA, Ali M, Mondal AC (2023) Neurobiology of depression in Parkinson\u2019s disease: insights into epidemiology, molecular mechanisms and treatment strategies. Ageing Res Rev 85:101840","journal-title":"Ageing Res Rev"},{"issue":"1","key":"1542_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s40001-024-01779-7","volume":"29","author":"B Alharbi","year":"2024","unstructured":"Alharbi B, Al-Kuraishy HM, Al-Gareeb AI, Elekhnawy E, Alharbi H, Alexiou A, Papadakis M, Batiha GE (2024) Role of GABA pathway in motor and non-motor symptoms in Parkinson\u2019s disease: a bidirectional circuit. Eur J Med Res 29(1):205","journal-title":"Eur J Med Res"},{"key":"1542_CR5","doi-asserted-by":"crossref","unstructured":"Almeida-Bezerra JW, Rodrigues FC, Lima Bezerra JJ, Vieira Pinheiro AA, Almeida de Menezes S, Tavares AB, Costa AR, Bezerra Morais-Braga P, Melo Coutinho HD, Teixeira de Albergaria E, Meiado MV, Siyadatpanah A, Kim B,\u00a0Morais de Oliveira AF (2022) Traditional uses, phytochemistry, and bioactivities of mesosphaerum suaveolens (L.) Kuntze. Evid Based Complement Alternat Med 2022: 3829180","DOI":"10.1155\/2022\/3829180"},{"key":"1542_CR6","doi-asserted-by":"publisher","first-page":"115408","DOI":"10.1016\/j.biopha.2023.115408","volume":"166","author":"R Amirian","year":"2023","unstructured":"Amirian R, Badrbani MA, Derakhshankhah H, Izadi Z, Shahbazi MA (2023) Targeted protein degradation for the treatment of Parkinson\u2019s disease: advances and future perspective. Biomed Pharmacother 166:115408","journal-title":"Biomed Pharmacother"},{"issue":"21","key":"1542_CR7","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1016\/j.jmb.2018.08.019","volume":"430","author":"SM Bell","year":"2018","unstructured":"Bell SM, Barnes K, Clemmens H, Al-Rafiah AR, Al-Ofi EA, Leech V, Bandmann O, Shaw PJ, Blackburn DJ, Ferraiuolo L, Mortiboys H (2018) Ursodeoxycholic acid improves mitochondrial function and redistributes Drp1 in fibroblasts from patients with either sporadic or familial Alzheimer\u2019s Disease. J Mol Biol 430(21):3942\u20133953","journal-title":"J Mol Biol"},{"issue":"10291","key":"1542_CR8","first-page":"2284","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s Disease Lancet 397(10291):2284\u20132303","journal-title":"Parkinson\u2019s Disease Lancet"},{"key":"1542_CR9","doi-asserted-by":"publisher","first-page":"101772","DOI":"10.1016\/j.pneurobio.2020.101772","volume":"187","author":"PJ Carling","year":"2020","unstructured":"Carling PJ, Mortiboys H, Green C, Mihaylov S, Sandor C, Schwartzentruber A, Taylor R, Wei W, Hastings C, Wong S, Lo C, Evetts S, Clemmens H, Wyles M, Willcox S, Payne T, Hughes R, Ferraiuolo L, Webber C, Hide W, Wade-Martins R, Talbot K, Hu MT, Bandmann O (2020) Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson\u2019s disease. Prog Neurobiol 187:101772","journal-title":"Prog Neurobiol"},{"issue":"2","key":"1542_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12035-012-8295-4","volume":"46","author":"M Castro-Caldas","year":"2012","unstructured":"Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CM, Gama MJ (2012) Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson\u2019s disease. Mol Neurobiol 46(2):475\u2013486","journal-title":"Mol Neurobiol"},{"issue":"5","key":"1542_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.31083\/j.jin2205132","volume":"22","author":"C Cattaneo","year":"2023","unstructured":"Cattaneo C, Jost WH (2023) Pain in Parkinson\u2019s Disease: pathophysiology, classification and treatment. J Integr Neurosci 22(5):132","journal-title":"J Integr Neurosci"},{"issue":"3","key":"1542_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3233\/JPD-225111","volume":"13","author":"LM Chahine","year":"2023","unstructured":"Chahine LM, Merchant K, Siderowf A, Sherer T, Tanner C, Marek K, Simuni T (2023) Proposal for a Biologic Staging System of Parkinson\u2019s Disease. J Parkinsons Dis 13(3):297\u2013309","journal-title":"J Parkinsons Dis"},{"key":"1542_CR13","volume-title":"Economic Burden of Parkinson's Disease: A Multinational","author":"KR Chaudhuri","year":"2024","unstructured":"Chaudhuri KR, Azulay JP, Odin P, Lindvall S, Domingos J, Alobaidi A, Kandukuri PL, Chaudhari VS, Parra JC, Yamazaki T, Oddsdottir J, Wright J, Martinez-Martin P (2024) Economic Burden of Parkinson\u2019s Disease: A Multinational. Real-World, Cost-of-Illness Study. Drugs Real World Outcomes"},{"issue":"7","key":"1542_CR14","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1080\/1028415X.2020.1859729","volume":"25","author":"E Cuevas","year":"2022","unstructured":"Cuevas E, Burks S, Raymick J, Robinson B, G\u00f3mez-Cris\u00f3stomo NP, Escudero-Lourdes C, Lopez AGG, Chigurupati S, Hanig J, Ferguson SA, Sarkar S (2022) Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson\u2019s disease. Nutr Neurosci 25(7):1374\u20131391","journal-title":"Nutr Neurosci"},{"key":"1542_CR15","first-page":"610","volume":"25","author":"A Daruich","year":"2019","unstructured":"Daruich A, Picard E, Boatright JH, Behar-Cohen F (2019) Review: the bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. Mol Vis 25:610\u2013624","journal-title":"Mol Vis"},{"key":"1542_CR16","doi-asserted-by":"crossref","unstructured":"Daruich A, Picard E, Gu\u00e9gan J, Jaworski T, Parenti L, Delaunay K, Naud MC, Berdugo M, Boatright JH, Behar-Cohen F (2022) Comparative analysis of Urso- and Tauroursodeoxycholic Acid Neuroprotective effects on Retinal Degeneration models. Pharmaceuticals (Basel) 15(3):334","DOI":"10.3390\/ph15030334"},{"key":"1542_CR17","doi-asserted-by":"crossref","unstructured":"Day JO, Mullin S (2021) The genetics of Parkinson\u2019s disease and implications for clinical practice. Genes (Basel) 12(7)","DOI":"10.3390\/genes12071006"},{"issue":"1","key":"1542_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JPD-212922","volume":"12","author":"BR De Miranda","year":"2022","unstructured":"De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER (2022) Preventing Parkinson\u2019s disease: an environmental agenda. J Parkinsons Dis 12(1):45\u201368","journal-title":"J Parkinsons Dis"},{"key":"1542_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jconrel.2020.02.033","volume":"321","author":"ER de Oliveira Junior","year":"2020","unstructured":"de Oliveira Junior ER, Truzzi E, Ferraro L, Fogagnolo M, Pavan B, Beggiato S, Rustichelli C, Maretti E, Lima EM, Leo E, Dalpiaz A (2020) Nasal administration of nanoencapsulated geraniol\/ursodeoxycholic acid conjugate: towards a new approach for the management of Parkinson\u2019s disease. J Control Release 321:540\u2013552","journal-title":"J Control Release"},{"issue":"12","key":"1542_CR20","doi-asserted-by":"publisher","first-page":"e0226748","DOI":"10.1371\/journal.pone.0226748","volume":"14","author":"T El-Hamoly","year":"2019","unstructured":"El-Hamoly T, Abd El-Rahman SS, Al-Abyad M (2019) Potential effects of ursodeoxycholic acid on accelerating cutaneous wound healing. PLoS ONE 14(12):e0226748","journal-title":"PLoS ONE"},{"issue":"8","key":"1542_CR21","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1007\/s12035-016-0145-3","volume":"54","author":"I Fonseca","year":"2017","unstructured":"Fonseca I, Gordino G, Moreira S, Nunes MJ, Azevedo C, Gama MJ, Rodrigues E, Rodrigues CMP, Castro-Caldas M (2017) Tauroursodeoxycholic acid protects against mitochondrial dysfunction and cell death via Mitophagy in Human Neuroblastoma cells. Mol Neurobiol 54(8):6107\u20136119","journal-title":"Mol Neurobiol"},{"issue":"6","key":"1542_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00702-023-02612-x","volume":"130","author":"T Gasser","year":"2023","unstructured":"Gasser T (2023) Genetic testing for Parkinson\u2019s disease in clinical practice. J Neural Transm (Vienna) 130(6):777\u2013782","journal-title":"J Neural Transm (Vienna)"},{"key":"1542_CR23","doi-asserted-by":"publisher","first-page":"107396","DOI":"10.1016\/j.pharmthera.2019.107396","volume":"203","author":"JF Goossens","year":"2019","unstructured":"Goossens JF, Bailly C (2019) Ursodeoxycholic acid and cancer: from chemoprevention to chemotherapy. Pharmacol Ther 203:107396","journal-title":"Pharmacol Ther"},{"key":"1542_CR24","doi-asserted-by":"crossref","unstructured":"Graham SF, Rey NL, Ugur Z, Yilmaz A, Sherman E, Maddens M, Bahado-Singh RO, Becker K, Schulz E, Meyerdirk LK, Steiner JA, Ma J, Brundin P (2018) Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson\u2019s Disease. Metabolites 8(4):71","DOI":"10.3390\/metabo8040071"},{"key":"1542_CR25","doi-asserted-by":"crossref","unstructured":"Grant SM, DeMorrow S (2020) Bile acid signaling in neurodegenerative and neurological disorders. Int J Mol Sci 21(17)","DOI":"10.3390\/ijms21175982"},{"issue":"7","key":"1542_CR26","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","volume":"132","author":"MT Hayes","year":"2019","unstructured":"Hayes MT (2019) Parkinson\u2019s disease and parkinsonism. Am J Med 132(7):802\u2013807","journal-title":"Am J Med"},{"issue":"23","key":"1542_CR27","doi-asserted-by":"publisher","first-page":"13693","DOI":"10.1021\/acs.chemrev.3c00479","volume":"123","author":"DR Hill","year":"2023","unstructured":"Hill DR, Huters AD, Towne TB, Reddy RE, Fogle JL, Voight EA, Kym PR (2023) Parkinson\u2019s Disease: advances in treatment and the syntheses of various classes of Pharmaceutical Drug Substances. Chem Rev 123(23):13693\u201313712","journal-title":"Chem Rev"},{"key":"1542_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/00365529409103618","volume":"204","author":"AF Hofmann","year":"1994","unstructured":"Hofmann AF (1994) Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl 204:1\u201315","journal-title":"Scand J Gastroenterol Suppl"},{"key":"1542_CR29","doi-asserted-by":"publisher","first-page":"100348","DOI":"10.1016\/j.bbih.2021.100348","volume":"18","author":"F Huang","year":"2021","unstructured":"Huang F (2021) Ursodeoxycholic acid as a potential alternative therapeutic approach for neurodegenerative disorders: effects on cell apoptosis, oxidative stress and inflammation in the brain. Brain Behav Immun Health 18:100348","journal-title":"Brain Behav Immun Health"},{"key":"1542_CR30","doi-asserted-by":"publisher","first-page":"1168144","DOI":"10.3389\/fphar.2023.1168144","volume":"14","author":"L Huang","year":"2023","unstructured":"Huang L, Wei W, Huang X, Li X, Liu H, Gui L, Jiang J, Wan L, Zhou X, Ding J, Jiang X, Zhang B, Lan K (2023) High-fat diets enhance and delay ursodeoxycholic acid absorption but elevate circulating hydrophobic bile salts. Front Pharmacol 14:1168144","journal-title":"Front Pharmacol"},{"issue":"8","key":"1542_CR31","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK (2020) Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91(8):795\u2013808","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1542_CR32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/WNF.0000000000000528","volume":"45","author":"C Jiang","year":"2022","unstructured":"Jiang C, Shen D, Li K, Wang H, Sang W, Qi H (2022) Protective effects of Ursodeoxycholic Acid against oxidative stress and Neuroinflammation through Mitogen-activated protein kinases pathway in MPTP-Induced Parkinson Disease. Clin Neuropharmacol 45(6):168\u2013174","journal-title":"Clin Neuropharmacol"},{"key":"1542_CR33","doi-asserted-by":"crossref","unstructured":"Jung HW, Hwang JH (2021) Anticancer effects of ursi fel extract and its active compound, ursodeoxycholic acid. FRO Anaplastic Thyroid Cancer Cells Molecules 26(17)","DOI":"10.3390\/molecules26175309"},{"issue":"1","key":"1542_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40035-022-00307-z","volume":"11","author":"K Khalaf","year":"2022","unstructured":"Khalaf K, Tornese P, Cocco A, Albanese A (2022) Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Transl Neurodegener 11(1):33","journal-title":"Transl Neurodegener"},{"issue":"22","key":"1542_CR36","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1212\/01.wnl.0000271880.27321.a7","volume":"69","author":"C Klein","year":"2007","unstructured":"Klein C, Schlossmacher MG (2007) Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69(22):2093\u20132104","journal-title":"Neurology"},{"issue":"11","key":"1542_CR37","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s11910-023-01312-z","volume":"23","author":"S Kola","year":"2023","unstructured":"Kola S, Subramanian I (2023) Updates in Parkinson\u2019s Disease Integrative therapies: an evidence-based review. Curr Neurol Neurosci Rep 23(11):717\u2013726","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"7","key":"1542_CR38","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2174\/1871527320666211006142100","volume":"21","author":"S Kumar","year":"2022","unstructured":"Kumar S, Goyal L, Singh S (2022) Tremor and rigidity in patients with Parkinson\u2019s disease: emphasis on Epidemiology, Pathophysiology and contributing factors. CNS Neurol Disord Drug Targets 21(7):596\u2013609","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1542_CR39","doi-asserted-by":"crossref","unstructured":"Kusaczuk M (2019) Tauroursodeoxycholate-bile acid with chaperoning activity: Molecular and Cellular effects and therapeutic perspectives. Cells 8(12):1471","DOI":"10.3390\/cells8121471"},{"issue":"12","key":"1542_CR40","doi-asserted-by":"publisher","first-page":"e14456","DOI":"10.14814\/phy2.14456","volume":"8","author":"NK Lajczak-McGinley","year":"2020","unstructured":"Lajczak-McGinley NK, Porru E, Fallon CM, Smyth J, Curley C, McCarron PA, Tambuwala MM, Roda A, Keely SJ (2020) The secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis. Physiol Rep 8(12):e14456","journal-title":"Physiol Rep"},{"issue":"8","key":"1542_CR41","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/jcph.1409","volume":"59","author":"S Lee","year":"2019","unstructured":"Lee S, Yoon S, Chung H, Ji SC, Yoon SH, Yu KS, Cho JY, Chung JY (2019) Pharmacokinetics of Ursodeoxycholic Acid in Elderly volunteers compared with younger adults in a Korean Population. J Clin Pharmacol 59(8):1085\u20131092","journal-title":"J Clin Pharmacol"},{"key":"1542_CR42","doi-asserted-by":"publisher","first-page":"594496","DOI":"10.3389\/fphar.2020.594496","volume":"11","author":"C Li","year":"2020","unstructured":"Li C, Zhang S, Li L, Hu Q, Ji S (2020) Ursodeoxycholic acid protects against Arsenic Induced Hepatotoxicity by the Nrf2 Signaling Pathway. Front Pharmacol 11:594496","journal-title":"Front Pharmacol"},{"key":"1542_CR43","doi-asserted-by":"crossref","unstructured":"Luxenburger A, Clemmens H, Hastings C, Harris LD, Ure EM, Cameron SA, Aasly J, Bandmann O, Weymouth-Wilson A, Furneaux RH, Mortiboys H (2022) 3\u03b1,7-Dihydroxy-14(13\u219212)abeo-5\u03b2,12\u03b1(H),13\u03b2(H)-cholan-24-oic Acids display neuroprotective properties in common forms of Parkinson\u2019s disease. Biomolecules 13(1)","DOI":"10.3390\/biom13010076"},{"issue":"4","key":"1542_CR44","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1042\/BST20170501","volume":"46","author":"R Macdonald","year":"2018","unstructured":"Macdonald R, Barnes K, Hastings C, Mortiboys H (2018) Mitochondrial abnormalities in Parkinson\u2019s disease and Alzheimer\u2019s disease: can mitochondria be targeted therapeutically? Biochem Soc Trans 46(4):891\u2013909","journal-title":"Biochem Soc Trans"},{"key":"1542_CR45","doi-asserted-by":"crossref","unstructured":"Maharjan P, Kim D, Jin M, Ko HJ, Song YH, Lee Y, Ahn BN, Kim SK, Lee Y, Shin MC, Min KA, Yang J (2019) Preclinical evaluation of UDCA-containing oral formulation in mice for the treatment of wet age-related macular degeneration. Pharmaceutics 11(11)","DOI":"10.3390\/pharmaceutics11110561"},{"issue":"10","key":"1542_CR46","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jpha.2023.06.007","volume":"13","author":"Z Mao","year":"2023","unstructured":"Mao Z, Hui H, Zhao X, Xu L, Qi Y, Yin L, Qu L, Han L, Peng J (2023) Protective effects of dioscin against Parkinson\u2019s disease via regulating bile acid metabolism through remodeling gut microbiome\/GLP-1 signaling. J Pharm Anal 13(10):1153\u20131167","journal-title":"J Pharm Anal"},{"key":"1542_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mcn.2019.01.003","volume":"96","author":"MO Mendes","year":"2019","unstructured":"Mendes MO, Rosa AI, Carvalho AN, Nunes MJ, Dion\u00edsio P, Rodrigues E, Costa D, Duarte-Silva S, Maciel P, Rodrigues CMP, Gama MJ, Castro-Caldas M (2019) Neurotoxic effects of MPTP on mouse cerebral cortex: modulation of neuroinflammation as a neuroprotective strategy. Mol Cell Neurosci 96:1\u20139","journal-title":"Mol Cell Neurosci"},{"key":"1542_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.expneurol.2017.05.009","volume":"295","author":"S Moreira","year":"2017","unstructured":"Moreira S, Fonseca I, Nunes MJ, Rosa A, Lemos L, Rodrigues E, Carvalho AN, Outeiro TF, Rodrigues CMP, Gama MJ, Castro-Caldas M (2017) Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson\u2019s disease. Exp Neurol 295:77\u201387","journal-title":"Exp Neurol"},{"issue":"Pt 10","key":"1542_CR49","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1093\/brain\/awt224","volume":"136","author":"H Mortiboys","year":"2013","unstructured":"Mortiboys H, Aasly J, Bandmann O (2013) Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson\u2019s disease. Brain 136(Pt 10):3038\u20133050","journal-title":"Brain"},{"issue":"10","key":"1542_CR50","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1212\/WNL.0000000000001905","volume":"85","author":"H Mortiboys","year":"2015","unstructured":"Mortiboys H, Furmston R, Bronstad G, Aasly J, Elliott C, Bandmann O (2015) UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. Neurology 85(10):846\u2013852","journal-title":"Neurology"},{"issue":"8","key":"1542_CR51","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/mds.29450","volume":"38","author":"T Payne","year":"2023","unstructured":"Payne T, Appleby M, Buckley E, van Gelder LMA, Mullish BH, Sassani M, Dunning MJ, Hernandez D, Scholz SW, McNeill A, Libri V, Moll S, Marchesi JR, Taylor R, Su L, Mazz\u00e0 C, Jenkins TM, Foltynie T, Bandmann O (2023) A Double-Blind, randomized, placebo-controlled trial of Ursodeoxycholic Acid (UDCA) in Parkinson\u2019s Disease. Mov Disord 38(8):1493\u20131502","journal-title":"Mov Disord"},{"issue":"2","key":"1542_CR52","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JPD-225060","volume":"13","author":"W Pirker","year":"2023","unstructured":"Pirker W, Katzenschlager R, Hallett M, Poewe W (2023) Pharmacological treatment of Tremor in Parkinson\u2019s Disease Revisited. J Parkinsons Dis 13(2):127\u2013144","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"1542_CR53","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1023\/B:JOBB.0000041771.66775.d5","volume":"36","author":"S Przedborski","year":"2004","unstructured":"Przedborski S, Tieu K, Perier C, Vila M (2004) MPTP as a mitochondrial neurotoxic model of Parkinson\u2019s disease. J Bioenerg Biomembr 36(4):375\u2013379","journal-title":"J Bioenerg Biomembr"},{"key":"1542_CR54","doi-asserted-by":"publisher","first-page":"135493","DOI":"10.1016\/j.neulet.2020.135493","volume":"741","author":"H Qi","year":"2021","unstructured":"Qi H, Shen D, Jiang C, Wang H, Chang M (2021) Ursodeoxycholic acid protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis in MPTP\/MPP(+)-induced Parkinson\u2019s disease. Neurosci Lett 741:135493","journal-title":"Neurosci Lett"},{"key":"1542_CR55","doi-asserted-by":"publisher","first-page":"101752","DOI":"10.1016\/j.jchemneu.2020.101752","volume":"104","author":"SN Rai","year":"2020","unstructured":"Rai SN, Singh P (2020) Advancement in the modelling and therapeutics of Parkinson\u2019s disease. J Chem Neuroanat 104:101752","journal-title":"J Chem Neuroanat"},{"key":"1542_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jchemneu.2015.12.002","volume":"71","author":"SN Rai","year":"2016","unstructured":"Rai SN, Yadav SK, Singh D, Singh SP (2016) Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced parkinsonian mouse model. J Chem Neuroanat 71:41\u201349","journal-title":"J Chem Neuroanat"},{"issue":"3","key":"1542_CR57","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s12640-019-00038-6","volume":"36","author":"SN Rai","year":"2019","unstructured":"Rai SN, Zahra W, Singh SS, Birla H, Keswani C, Dilnashin H, Rathore AS, Singh R, Singh RK, Singh SP (2019) Anti-inflammatory activity of Ursolic Acid in MPTP-Induced Parkinsonian Mouse Model. Neurotox Res 36(3):452\u2013462","journal-title":"Neurotox Res"},{"issue":"5","key":"1542_CR58","first-page":"626","volume":"42","author":"S Rajan","year":"2022","unstructured":"Rajan S, Kaas B (2022) Parkinson\u2019s Disease. Risk Factor Modif Prev Semin Neurol 42(5):626\u2013638","journal-title":"Risk Factor Modif Prev Semin Neurol"},{"key":"1542_CR59","doi-asserted-by":"crossref","unstructured":"Ramakrishna K, Nalla LV, Naresh D, Venkateswarlu K, Viswanadh MK, Nalluri BN, Chakravarthy G, Duguluri S, Singh P, Rai SN, Kumar A, Singh V, Singh SK (2023) WNT-\u03b2 Catenin signaling as a potential therapeutic target for neurodegenerative diseases: current status and future perspective. Diseases 11(3)","DOI":"10.3390\/diseases11030089"},{"key":"1542_CR60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lfs.2019.03.057","volume":"226","author":"C Raza","year":"2019","unstructured":"Raza C, Anjum R, Shakeel NUA (2019) Parkinson\u2019s disease: mechanisms, translational models and management strategies. Life Sci 226:77\u201390","journal-title":"Life Sci"},{"issue":"2","key":"1542_CR61","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.mcna.2018.10.014","volume":"103","author":"SG Reich","year":"2019","unstructured":"Reich SG, Savitt JM (2019) Parkinson\u2019s disease. Med Clin North Am 103(2):337\u2013350","journal-title":"Med Clin North Am"},{"key":"1542_CR62","doi-asserted-by":"publisher","first-page":"744488","DOI":"10.3389\/fphar.2021.744488","volume":"12","author":"M Robles-D\u00edaz","year":"2021","unstructured":"Robles-D\u00edaz M, Nezic L, Vujic-Aleksic V, Bj\u00f6rnsson ES (2021) Role of Ursodeoxycholic Acid in Treating and preventing Idiosyncratic Drug-Induced Liver Injury. Syst Rev Front Pharmacol 12:744488","journal-title":"Syst Rev Front Pharmacol"},{"issue":"6","key":"1542_CR63","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1046\/j.1471-4159.2000.0752368.x","volume":"75","author":"CM Rodrigues","year":"2000","unstructured":"Rodrigues CM, Stieers CL, Keene CD, Ma X, Kren BT, Low WC, Steer CJ (2000) Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J Neurochem 75(6):2368\u20132379","journal-title":"J Neurochem"},{"issue":"9","key":"1542_CR64","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.bbadis.2017.06.004","volume":"1863","author":"AI Rosa","year":"2017","unstructured":"Rosa AI, Fonseca I, Nunes MJ, Moreira S, Rodrigues E, Carvalho AN, Rodrigues CMP, Gama MJ, Castro-Caldas M (2017) Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson\u2019s disease. Biochim Biophys Acta Mol Basis Dis 1863(9):2171\u20132181","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"12","key":"1542_CR65","doi-asserted-by":"publisher","first-page":"9139","DOI":"10.1007\/s12035-018-1062-4","volume":"55","author":"AI Rosa","year":"2018","unstructured":"Rosa AI, Duarte-Silva S, Silva-Fernandes A, Nunes MJ, Carvalho AN, Rodrigues E, Gama MJ, Rodrigues CMP, Maciel P, Castro-Caldas M (2018) Tauroursodeoxycholic acid improves motor symptoms in a mouse model of Parkinson\u2019s Disease. Mol Neurobiol 55(12):9139\u20139155","journal-title":"Mol Neurobiol"},{"issue":"6","key":"1542_CR66","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/jcph.1575","volume":"60","author":"AG Sathe","year":"2020","unstructured":"Sathe AG, Tuite P, Chen C, Ma Y, Chen W, Cloyd J, Low WC, Steer CJ, Lee BY, Zhu XH, Coles LD (2020) Pharmacokinetics, Safety, and tolerability of orally administered ursodeoxycholic acid in patients with Parkinson\u2019s Disease-A Pilot Study. J Clin Pharmacol 60(6):744\u2013750","journal-title":"J Clin Pharmacol"},{"issue":"8649","key":"1542_CR67","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(89)92366-0","volume":"1","author":"AH Schapira","year":"1989","unstructured":"Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson\u2019s disease. Lancet 1(8649):1269","journal-title":"Lancet"},{"issue":"3","key":"1542_CR68","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/MOL.0000000000000303","volume":"27","author":"M Schonewille","year":"2016","unstructured":"Schonewille M, de Boer JF, Groen AK (2016) Bile salts in control of lipid metabolism. Curr Opin Lipidol 27(3):295\u2013301","journal-title":"Curr Opin Lipidol"},{"key":"1542_CR69","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3389\/fphar.2018.00757","volume":"9","author":"SS Singh","year":"2018","unstructured":"Singh SS, Rai SN, Birla H, Zahra W, Kumar G, Gedda MR, Tiwari N, Patnaik R, Singh RK, Singh SP (2018) Effect of Chlorogenic Acid Supplementation in MPTP-Intoxicated mouse. Front Pharmacol 9:757","journal-title":"Front Pharmacol"},{"key":"1542_CR70","doi-asserted-by":"crossref","unstructured":"Singh SS, Rai SN, Birla H, Zahra W, Rathore AS, Dilnashin H, Singh R, Singh SP (2020) Neuroprotective effect of chlorogenic acid on mitochondrial dysfunction-mediated apoptotic death of da neurons in a Parkinsonian mouse model. Oxid Med Cell Longev 2020: 6571484","DOI":"10.1155\/2020\/6571484"},{"issue":"8","key":"1542_CR71","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/JPER.19-0013","volume":"91","author":"R Talebian","year":"2020","unstructured":"Talebian R, Panahipour L, Gruber R (2020) Ursodeoxycholic acid attenuates the expression of proinflammatory cytokines in periodontal cells. J Periodontol 91(8):1098\u20131104","journal-title":"J Periodontol"},{"issue":"3","key":"1542_CR72","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s12035-014-8731-8","volume":"51","author":"AR Vaz","year":"2015","unstructured":"Vaz AR, Cunha C, Gomes C, Schmucki N, Barbosa M, Brites D (2015) Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol Neurobiol 51(3):864\u2013877","journal-title":"Mol Neurobiol"},{"key":"1542_CR73","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev-biochem-071322-021330","volume":"92","author":"S Vrijsen","year":"2023","unstructured":"Vrijsen S, Houdou M, Cascalho A, Eggermont J, Vangheluwe P (2023) Polyamines in Parkinson\u2019s Disease: balancing between neurotoxicity and neuroprotection. Annu Rev Biochem 92:435\u2013464","journal-title":"Annu Rev Biochem"},{"key":"1542_CR74","doi-asserted-by":"publisher","first-page":"105047","DOI":"10.1016\/j.nbd.2020.105047","volume":"144","author":"RJH West","year":"2020","unstructured":"West RJH, Ugbode C, Fort-Aznar L, Sweeney ST (2020) Neuroprotective activity of ursodeoxycholic acid in CHMP2B(Intron5) models of frontotemporal dementia. Neurobiol Dis 144:105047","journal-title":"Neurobiol Dis"},{"key":"1542_CR75","doi-asserted-by":"crossref","unstructured":"Winston JA, Rivera AJ, Cai J, Thanissery R, Montgomery SA, Patterson AD, Theriot CM (2020) Ursodeoxycholic Acid (UDCA) mitigates the host inflammatory response during Clostridioides difficile infection by altering gut bile acids. Infect Immun 88(6):e00045\u201320","DOI":"10.1128\/IAI.00045-20"},{"issue":"3","key":"1542_CR76","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.bbrc.2020.05.128","volume":"529","author":"P Wu","year":"2020","unstructured":"Wu P, Zhao J, Guo Y, Yu Y, Wu X, Xiao H (2020) Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK. Biochem Biophys Res Commun 529(3):834\u2013838","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1542_CR77","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13578-023-01053-z","volume":"13","author":"C Xing","year":"2023","unstructured":"Xing C, Huang X, Wang D, Yu D, Hou S, Cui H, Song L (2023) Roles of bile acids signaling in neuromodulation under physiological and pathological conditions. Cell Biosci 13(1):106","journal-title":"Cell Biosci"},{"key":"1542_CR78","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/bs.irn.2019.06.003","volume":"147","author":"X Xu","year":"2019","unstructured":"Xu X, Fu Z, Le W (2019) Exercise and Parkinson\u2019s disease. Int Rev Neurobiol 147:45\u201374","journal-title":"Int Rev Neurobiol"},{"issue":"9","key":"1542_CR79","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1021\/acschemneuro.0c00095","volume":"11","author":"Z Yao","year":"2020","unstructured":"Yao Z, Zhang X, Zhao F, Wang S, Chen A, Huang B, Wang J, Li X (2020) Ursodeoxycholic acid inhibits glioblastoma progression via endoplasmic reticulum stress related apoptosis and synergizes with the proteasome inhibitor Bortezomib. ACS Chem Neurosci 11(9):1337\u20131346","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"1542_CR80","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cpdd.790","volume":"10","author":"S Yoon","year":"2021","unstructured":"Yoon S, Lee H, Ji SC, Yoon SH, Cho JY, Chung JY (2021) Pharmacokinetics and pharmacodynamics of Ursodeoxycholic Acid in an overweight Population with abnormal liver function. Clin Pharmacol Drug Dev 10(1):68\u201377","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"1542_CR81","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2174\/1871527319666200812224457","volume":"19","author":"W Zahra","year":"2020","unstructured":"Zahra W, Rai SN, Birla H, Singh SS, Rathore AS, Dilnashin H, Singh R, Keswani C, Singh RK, Singh SP (2020) Neuroprotection of Rotenone-Induced parkinsonism by Ursolic Acid in PD Mouse Model. CNS Neurol Disord Drug Targets 19(7):527\u2013540","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1542_CR82","doi-asserted-by":"publisher","first-page":"119252","DOI":"10.1016\/j.lfs.2021.119252","volume":"272","author":"L Zangerolamo","year":"2021","unstructured":"Zangerolamo L, Vettorazzi JF, Rosa LRO, Carneiro EM, Barbosa HCL (2021) The bile acid TUDCA and neurodegenerative disorders: an overview. Life Sci 272:119252","journal-title":"Life Sci"},{"key":"1542_CR83","doi-asserted-by":"crossref","unstructured":"Zappaterra F, Costa S, Summa D, Semeraro B, Cristofori V, Trapella C, Tamburini E (2021) Glyceric Prodrug of Ursodeoxycholic Acid (UDCA): Novozym 435-Catalyzed synthesis of UDCA-Monoglyceride. Molecules 26(19):5966","DOI":"10.3390\/molecules26195966"},{"issue":"1","key":"1542_CR84","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41420-021-00589-8","volume":"7","author":"H Zhang","year":"2021","unstructured":"Zhang H, Xu H, Zhang C, Tang Q, Bi F (2021) Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis. Cell Death Discov 7(1):207","journal-title":"Cell Death Discov"},{"key":"1542_CR85","doi-asserted-by":"crossref","unstructured":"Zhu XH, Lee BY, Tuite P, Coles L, Sathe AG, Chen C, Cloyd J, Low WC, Steer CJ, Chen W (2021) Quantitative Assessment of Occipital Metabolic and Energetic Changes in Parkinson\u2019s Patients, Using In Vivo (31)P MRS-Based Metabolic Imaging at 7T. Metabolites 11(3)","DOI":"10.3390\/metabo11030145"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-025-01542-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-025-01542-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-025-01542-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T09:43:43Z","timestamp":1740822223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-025-01542-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":84,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["1542"],"URL":"https:\/\/doi.org\/10.1007\/s11011-025-01542-9","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declaration of generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}